Literature DB >> 24787518

Testosterone, cardiovascular risk, and hormonophobia.

Abraham Morgentaler1.   

Abstract

INTRODUCTION: A public outcry against testosterone (T) therapy has suddenly occurred based on two reports suggesting treatment was associated with increased cardiovascular (CV) risks. AIM: To analyze scientific and social bases for concerns regarding T therapy.
METHODS: Analysis of recent articles regarding CV risks with T and comparison with events surrounding publication of results of the Women's Health Initiative in 2002.
RESULTS: In the first study, the percentage of individuals with an adverse event was lower by half in men who received T compared with untreated men (10.1% vs. 21.2%). However, an opposite conclusion was reached via complex statistics. The second study reported minor increased rate of nonfatal myocardial infarction (MI) up to 90 days after receiving a T prescription compared with the prior 12 months. However, there was no control group, so it is unknown whether this MI rate was increased, reduced, or unchanged compared with untreated men. Neither study provided substantive evidence of risk, yet these were lauded as proof of dangers, despite a substantial literature to the contrary. Similar events followed the publication of the Women's Health Initiative in 2002 when a media frenzy over increased risks with female hormone replacement therapy obscured the fact that the reported excess risk was clinically meaningless, at two events per 1,000 person-years. Stakeholders driving concerns regarding hormone risks are unlikely to be clinicians with real-world patient experience.
CONCLUSIONS: The use of weak studies as proof of danger indicates that cultural (i.e., nonscientific) forces are at play. Negative media stories touting T's risks appear fueled by antipharma sentiment, anger against aggressive marketing, and antisexuality. This stance is best described as "hormonophobia." As history shows, evidence alone may be insufficient to alter a public narrative. The true outrage is that social forces and hysteria have combined to deprive men of a useful treatment without regard for medical science.
© 2014 International Society for Sexual Medicine.

Entities:  

Keywords:  Bias; Cardiovascular Risk; Heart Attack; Mortality; Stroke; Testosterone

Mesh:

Substances:

Year:  2014        PMID: 24787518     DOI: 10.1111/jsm.12556

Source DB:  PubMed          Journal:  J Sex Med        ISSN: 1743-6095            Impact factor:   3.802


  7 in total

Review 1.  Review of health risks of low testosterone and testosterone administration.

Authors:  Huanguang Jia; Charles T Sullivan; Sean C McCoy; Joshua F Yarrow; Matthew Morrow; Stephen E Borst
Journal:  World J Clin Cases       Date:  2015-04-16       Impact factor: 1.337

Review 2.  Erectile dysfunction.

Authors:  Faysal A Yafi; Lawrence Jenkins; Maarten Albersen; Giovanni Corona; Andrea M Isidori; Shari Goldfarb; Mario Maggi; Christian J Nelson; Sharon Parish; Andrea Salonia; Ronny Tan; John P Mulhall; Wayne J G Hellstrom
Journal:  Nat Rev Dis Primers       Date:  2016-02-04       Impact factor: 52.329

Review 3.  The practical management of testosterone deficiency in men.

Authors:  Antonio Aversa; Abraham Morgentaler
Journal:  Nat Rev Urol       Date:  2015-10-13       Impact factor: 14.432

4.  Myocardial Infarction and Stroke Risk in Young Healthy Men Treated with Injectable Testosterone.

Authors:  Robert S Tan; Kelly R Cook; William G Reilly
Journal:  Int J Endocrinol       Date:  2015-06-01       Impact factor: 3.257

5.  PADAMboom!!!

Authors:  Stefan Buntrock
Journal:  Cent European J Urol       Date:  2014

6.  Improvement of endothelial function following initiation of testosterone replacement therapy.

Authors:  Daniel A Shoskes; Barbara Tucky; Allan S Polackwich
Journal:  Transl Androl Urol       Date:  2016-12

Review 7.  Late-onset hypogonadism.

Authors:  Piotr Dudek; Jarosław Kozakowski; Wojciech Zgliczyński
Journal:  Prz Menopauzalny       Date:  2017-06-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.